Literature DB >> 33707492

Robotic assisted CyberKnife radiosurgery for the treatment of iris melanoma.

Valerie Schmelter1, Sarah Heidorn2, Alexander Muacevic2, Siegfried G Priglinger1, Paul Foerster1, Raffael Liegl3.   

Abstract

Iris melanoma is a rare form of uveal melanoma with potential metastic spread. Treatment options include surgical resection, enucleation or irradiation. We analysed visual outcome, complication appearance and management in eight patients with iris melanoma following robotic-assisted CyberKnife treatment. Consecutive patients from the Department of Ophthalmology at University of Munich were included in the study if they had an iris melanoma that was treated with CyberKnife and had a minimum follow-up of 12 months. We evaluated tumor thickness, largest diameter, visual acuity and complications. 8 patients were included in this report. The median age was 74 years (range: 53-86 years). The median follow-up was 23 months (range 12-48 months). Tumor thickness decreased from 2.1 to 1.4 mm on average. Four out of eight patients showed stable or increased visual acuity compared to visual acuity at first visit. We did not find a correlation of applied radiation volume or radiation dose on visual outcome. Radiation keratopathy was the most common complication in five patients. No recurrences were noted. Robotic-assisted radiosurgery following CyberKnife is a promising non-invasive, single session treatment option for iris melanoma with comparable results regarding recurrence rate or complications to brachytherapy and proton beam therapy. All included patients showed good visual outcome.

Entities:  

Mesh:

Year:  2021        PMID: 33707492      PMCID: PMC7952409          DOI: 10.1038/s41598-021-84290-x

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  28 in total

1.  Surgical treatment of iris and ciliary body melanoma: follow-up of a 25-year series of patients.

Authors:  Stefan Klauber; Peter K Jensen; Jan U Prause; Svend V Kessing
Journal:  Acta Ophthalmol       Date:  2010-04-28       Impact factor: 3.761

2.  Proton therapy of iris melanoma with 50 CGE : Influence of target volume on clinical outcome.

Authors:  Aline I Riechardt; Bettina Karle; Dino Cordini; Jens Heufelder; Volker Budach; Antonia M Joussen; Johannes Gollrad
Journal:  Strahlenther Onkol       Date:  2017-06-19       Impact factor: 3.621

3.  Ruthenium plaque radiation therapy for iris and iridociliary melanomas.

Authors:  Lubna Razzaq; Jan E E Keunen; Nicoline E Schalij-Delfos; Carien L Creutzberg; Martijn Ketelaars; Rob J W de Keizer
Journal:  Acta Ophthalmol       Date:  2010-07-29       Impact factor: 3.761

4.  Plaque radiotherapy treatment with ruthenium-106 for iris malignant melanoma.

Authors:  M Tsimpida; J Hungerford; A Arora; V Cohen
Journal:  Eye (Lond)       Date:  2011-09-23       Impact factor: 3.775

5.  Proton Beam Therapy for Iris Melanomas in 107 Patients.

Authors:  Juliette Thariat; Ahmed Rahmi; Julia Salleron; Carlo Mosci; Benjamin Butet; Celia Maschi; Francesco Lanza; Sara Lanteri; Stephanie Baillif; Joel Herault; Thibaud Mathis; Jean Pierre Caujolle
Journal:  Ophthalmology       Date:  2017-11-08       Impact factor: 12.079

6.  Ruthenium-106 brachytherapy for iris and iridociliary melanomas.

Authors:  Marina Marinkovic; Nanda Horeweg; Mirjam S Laman; Jaco C Bleeker; Martijn Ketelaars; Femke P Peters; Gre P M Luyten; Carien L Creutzberg
Journal:  Br J Ophthalmol       Date:  2017-11-09       Impact factor: 4.638

7.  Management of iris melanomas with 125Iodine plaque radiotherapy.

Authors:  Bruno F Fernandes; Hatem Krema; Emiliano Fulda; Charles J Pavlin; David G Payne; Hugh D McGowan; Ernest Rand Simpson
Journal:  Am J Ophthalmol       Date:  2009-11-04       Impact factor: 5.258

8.  Management of patients with uveal metastases at the Liverpool Ocular Oncology Centre.

Authors:  Lazaros Konstantinidis; Iwona Rospond-Kubiak; Ignacio Zeolite; Heinrich Heimann; Carl Groenewald; Sarah E Coupland; Bertil Damato
Journal:  Br J Ophthalmol       Date:  2013-10-29       Impact factor: 4.638

9.  Iris Melanoma Outcomes Based on the American Joint Committee on Cancer Classification (Eighth Edition) in 432 Patients.

Authors:  Carol L Shields; Maura Di Nicola; Vladislav P Bekerman; Swathi Kaliki; Carolina Alarcon; Enzo Fulco; Jerry A Shields
Journal:  Ophthalmology       Date:  2018-01-17       Impact factor: 12.079

10.  Risk of ocular melanoma in relation to cutaneous and iris naevi.

Authors:  V Bataille; P Sasieni; J Cuzick; J L Hungerford; A Swerdlow; J A Bishop
Journal:  Int J Cancer       Date:  1995-03-03       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.